Iconovo AB (OSTO:ICO) Total Liabilities: kr15.48 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ICO Iconovo AB OSTO:ICO
34 GF Score
Price kr1.08
GF Value kr0.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Iconovo AB Total Liabilities?

Iconovo AB OSTO:ICO -0.92% 34 Total Liabilities is kr15.48 Mil as of Mar. 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Iconovo AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr15.48 Mil.

Iconovo AB's quarterly Total Liabilities increased from Sep. 2025 (kr11.65 Mil) to Dec. 2025 (kr13.16 Mil) and increased from Dec. 2025 (kr13.16 Mil) to Mar. 2026 (kr15.48 Mil).

Iconovo AB's annual Total Liabilities increased from Dec. 2023 (kr14.55 Mil) to Dec. 2024 (kr16.47 Mil) but then declined from Dec. 2024 (kr16.47 Mil) to Dec. 2025 (kr13.16 Mil).

Iconovo AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Iconovo AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iconovo AB Total Liabilities Chart

Iconovo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.51 32.06 14.55 16.47 13.16

Iconovo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.69 16.88 11.65 13.16 15.48
OSTO:ICO
34GF Score
Iconovo AB OSTO:ICO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iconovo AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Iconovo AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.901+(1.261+1.1102230246252E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.16

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=131.084-117.922
=13.16

Iconovo AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.313+(2.168+-8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=15.48

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=173.247-157.766
=15.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr15.48 Mil mean?
Iconovo AB (OSTO:ICO) has a Total Liabilities of kr15.48 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Iconovo AB and its competitors.
Is Iconovo AB's Total Liabilities too high?
Iconovo AB's current Total Liabilities is kr15.48 Mil. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Total Liabilities compare to ABT and SYK?
Iconovo AB's Total Liabilities of kr15.48 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Iconovo AB and its competitors. Iconovo AB's current Total Liabilities is kr15.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr1.08 — trading 300% above its estimated fair value. The current Total Liabilities is kr15.48 Mil. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Total Liabilities is kr15.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iconovo AB (OSTO:ICO) Overvalued in 2026?

Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued. The current stock price of kr1.08 is trading 300% above its estimated GF Value™ of kr0.27. GuruFocus considers Iconovo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ICO:

  • Total Liabilities: kr15.48 Mil
  • GF Value™: kr0.27 vs. price of kr1.08 (300% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iconovo AB Business Description

Address Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score

Get the complete analysis for OSTO:ICO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.08
Price
kr0.27
GF Value